This Article Abstract Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Prystowsky, E. N. Articles by Wolff, A. A. Search for Related Content PubMed PubMed Citation Articles by Prystowsky, E. N. Articles by Wolff, A. A.

Termination of paroxysmal supraventricular tachycardia by tecadenoson (CVT-510),a novel A₁-adenosine receptor agonist

Eric N. Prystowsky, MD^*,*, Imran Niazi, MD, Anne B. Curtis, MD, David J. Wilber, MD, Tristram Bahnson, MD^||, Kenneth Ellenbogen, MD^¶, Anwer Dhala, MD^#, Daniel M. Bloomfield, MD^**, Michael Gold, MD, Alan Kadish, MD, Richard I. Fogel, MD^*, Mario D. Gonzalez, MD, Luiz Belardinelli, MD, Revati Shreeniwas, MD and Andrew A. Wolff, MD

^* Care Group, Indianapolis, Indiana, USA
Cardiology Division, St. Luke's Hospital, Milwaukee, Wisconsin, USA
Cardiology Division, University of Florida, Gainesville, Florida, USA
Cardiology Division, Loyola University Medical Center, Chicago, Illinois, USA
^|| Cardiology Division, Duke Medical Center, Durham, North Carolina, USA
^¶ Cardiology Division, Medical College of Virginia, Richmond, Virginia, USA
^# Heart Care Associates, Milwaukee, Wisconsin, USA
^** Cardiology Division, Columbia University, New York, New York, USA
Cardiology Division, University of Maryland, Baltimore, Maryland, USA
Cardiology Division, Northwestern University, Chicago, Illinois, USA
CV Therapeutics, Inc., Palo Alto, California, USA

View larger version (53K): [in a new window]   Figure 1 Summary of the conversion of paroxysmal supraventricular tachycardia to sinus rhythm by tecadenoson. Conversion rates (in percentages) after the first (stippled bars) and second (unfilled bars) boluses of tecadenoson are shown. The dose of tecadenoson (µg/kg) administered is indicated below each bar, and the numbers under the doses denote the number of patients treated at each dose level. Data from one patient dosed at 3 µg/kg who did not convert to sinus rhythm is not represented here.